1500 related articles for article (PubMed ID: 19388534)
1. [Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007--results of multicenter Polish study].
Jahnz-Rózyk K; Targowski T; From S
Pol Merkur Lekarski; 2009 Mar; 26(153):208-14. PubMed ID: 19388534
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of outpatient and inpatient costs of moderate and severe exacerbations of chronic obstructive pulmonary disease in Poland].
Jahnz-Rózyk K; Targowski T; From S
Pneumonol Alergol Pol; 2008; 76(6):426-31. PubMed ID: 19173191
[TBL] [Abstract][Full Text] [Related]
3. Cost analysis of chronic obstructive pulmonary disease in a tertiary care setting in Taiwan.
Chiang CH
Respirology; 2008 Sep; 13(5):689-94. PubMed ID: 18513247
[TBL] [Abstract][Full Text] [Related]
4. [Costs of chronic obstructive pulmonary disease in patients treated in ambulatory care in Poland].
Jahnz-Różyk K; Targowski T; From S; Faluta T; Borowiec L
Pneumonol Alergol Pol; 2011; 79(5):337-42. PubMed ID: 21861257
[TBL] [Abstract][Full Text] [Related]
5. [Retrospective analysis of direct costs of hospital treatment of chronic obstructive pulmonary disease exacerbations].
Jahnz-Rózyk K; Targowski T; From S; Płusa T
Pol Merkur Lekarski; 2004 May; 16 Suppl 1():91-4. PubMed ID: 15524028
[TBL] [Abstract][Full Text] [Related]
6. The cost of moderate and severe COPD exacerbations to the Canadian healthcare system.
Mittmann N; Kuramoto L; Seung SJ; Haddon JM; Bradley-Kennedy C; Fitzgerald JM
Respir Med; 2008 Mar; 102(3):413-21. PubMed ID: 18086519
[TBL] [Abstract][Full Text] [Related]
7. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review.
Toy EL; Gallagher KF; Stanley EL; Swensen AR; Duh MS
COPD; 2010 Jun; 7(3):214-28. PubMed ID: 20486821
[TBL] [Abstract][Full Text] [Related]
8. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of clinical effectiveness and direct costs of azithromycin treatment for exacerbation of chronic obstructive pulmonary disease in hospitalized patients and ambulatory care].
Faber M; Jahnz-Rózyk K; Kucharczyk A; Targowski T; From S; Mamełka B
Pol Merkur Lekarski; 2004 May; 16 Suppl 1():96-9. PubMed ID: 15524029
[TBL] [Abstract][Full Text] [Related]
10. The cost of treating patients with COPD in Denmark--a population study of COPD patients compared with non-COPD controls.
Bilde L; Rud Svenning A; Dollerup J; Baekke Borgeskov H; Lange P
Respir Med; 2007 Mar; 101(3):539-46. PubMed ID: 16889949
[TBL] [Abstract][Full Text] [Related]
11. Economic aspects of antimicrobial therapy of acute exacerbations of COPD.
Simoens S; Decramer M; Laekeman G
Respir Med; 2007 Jan; 101(1):15-26. PubMed ID: 16650975
[TBL] [Abstract][Full Text] [Related]
12. [Relationship between disease severity, smoking index age and direct costs of hospital treatment of COPD exacerbations].
Targowski T; Jahnz-Rózyk K; From S; Płusa T
Pneumonol Alergol Pol; 2005; 73(1):32-5. PubMed ID: 16539181
[TBL] [Abstract][Full Text] [Related]
13. Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis.
Yu AP; Yang H; Wu EQ; Setyawan J; Mocarski M; Blum S
J Med Econ; 2011; 14(3):315-23. PubMed ID: 21500975
[TBL] [Abstract][Full Text] [Related]
14. [Active tobacco smoking as determinant of costs of inpatient treatment of COPD exacerbations].
Targowski T; Jahnz-Rózyk K; From S; Płusa T
Przegl Lek; 2004; 61(10):1049-51. PubMed ID: 15794248
[TBL] [Abstract][Full Text] [Related]
15. Healthcare costs of COPD in Italian referral centres: a prospective study.
Koleva D; Motterlini N; Banfi P; Garattini L;
Respir Med; 2007 Nov; 101(11):2312-20. PubMed ID: 17681461
[TBL] [Abstract][Full Text] [Related]
16. Costs of chronic obstructive pulmonary disease (COPD) in Italy: the SIRIO study (social impact of respiratory integrated outcomes).
Dal Negro RW; Tognella S; Tosatto R; Dionisi M; Turco P; Donner CF
Respir Med; 2008 Jan; 102(1):92-101. PubMed ID: 17881206
[TBL] [Abstract][Full Text] [Related]
17. Economic burden of chronic obstructive pulmonary disease.
Teo WS; Tan WS; Chong WF; Abisheganaden J; Lew YJ; Lim TK; Heng BH
Respirology; 2012 Jan; 17(1):120-6. PubMed ID: 21954985
[TBL] [Abstract][Full Text] [Related]
18. Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease.
Dalal AA; Shah M; Lunacsek O; Hanania NA
Respir Med; 2011 Oct; 105(10):1516-22. PubMed ID: 21684731
[TBL] [Abstract][Full Text] [Related]
19. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore.
Lee KH; Phua J; Lim TK
Respir Med; 2006 Dec; 100(12):2190-6. PubMed ID: 16635566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
